Study shows that RNA can be targeted by small molecule drugs, creating new possibilities for disease treatment —


RNA (ribonucleic acid) performs many roles in human well being, and now a examine within the journal Nature affords highly effective proof that RNA may be a viable goal for drug growth. This work, led by researchers at Massachusetts Common Hospital (MGH), suggests {that a} new class of organic elements numbering within the 1000’s will be focused and thereby heralds a brand new period in drug growth.

Practically all medicine at present out there goal one in every of roughly 700 disease-related proteins among the many roughly 20,000 human proteins recognized by the Human Genome Venture. Nonetheless, lately there was rising curiosity in increasing the checklist of “druggable” targets to incorporate RNA. In cells, DNA (deoxyribonucleic acid) carries the genetic code for forming proteins. A section of DNA is copied, or transcribed, right into a “coding” RNA, which is in flip translated into protein. Nonetheless, the overwhelming majority of RNA within the human genome — 98 % — is “noncoding.”

“These noncoding RNAs play crucial roles within the genome, and we now perceive that mutations on this noncoding house may end up in illness,” says the senior writer of the Nature paper, Jeannie Lee, MD, PhD, of the Division of Molecular Biology at MGH. “And there could also be way more of those RNA genes than there are protein-coding genes. If we might goal these RNAs, we might vastly improve the universe through which we will discover medicine to deal with sufferers.”

Nonetheless, the pharmaceutical business has traditionally been hesitant to pursue RNA as a drug goal. Proteins are likely to have steady shapes, or conformations, which make them optimum targets: Medicine bind to proteins like a key in a lock. Against this, explains Lee, RNA tends to be extremely versatile, or “floppy,” and able to assuming a number of conformations. “If a lock is consistently altering form, your key just isn’t going to work,” says Lee. Noncoding RNA’s unstable nature has made corporations reluctant to spend money on attempting to develop drugs that concentrate on it. Nonetheless, it is recognized that some areas on RNA retain steady conformations, regardless of all of that shape-shifting, however discovering such areas has been a problem.

Lee directs a molecular biology lab at MGH, the place she and her crew examine RNA and its position in a organic course of known as X-chromosome inactivation (XCI), which deactivates one copy of the X chromosome in feminine mammals and is important for regular growth. In a examine led by postdoctoral fellow Rodrigo Aguilar, PhD, Lee’s group collaborated with colleagues at Merck Analysis Laboratories to seek out out if RNA could possibly be a viable drug goal. The main target of the examine was a type of noncoding RNA known as Xist, which silences genes on the X chromosome. Discovering a approach to intervene with this course of and reactivate a dormant X chromosome might assist information growth of remedies for genetic issues attributable to mutations on the X chromosome (referred to as X-linked issues), similar to Rett syndrome and Fragile X syndrome.

Along with Merck scientists Kerrie Spencer and Elliott Nickbarg, the MGH crew screened Xist towards a library of fifty,000 small molecule compounds and located a number of that bind to a area known as Repeat A (RepA) on Xist. One compound, which Lee’s crew named X1, had significantly fascinating qualities: It prevented a number of key proteins, PRC2 and SPEN, from binding to RepA, which is important for Xist to silence the X chromosome. “In consequence, X inactivation can’t happen,” says Lee. To know why, the crew collaborated with structural biologists led by Trushar Patel of the College of Lethbridge in Canada. Usually, Xist’s RepA can assume 16 completely different conformations, however X1 brought on it to undertake a extra uniform form. This structural change prevented RepA from binding with PRC2 and SPEN.

The method employed on this examine could possibly be used to establish different RNA-targeting medicine. “This actually opens up a big universe for brand spanking new drug growth,” says Lee. “Now we do not simply have 700 proteins to focus on utilizing small molecules. Sooner or later, we might have tens and probably a whole bunch of 1000’s of RNAs to focus on to remedy illness.”

Lee can be a professor of Genetics at Harvard Medical Faculty. Aguilar is now an assistant professor and researcher at Andres Bello College in Santiago, Chile.

Funding for this work got here from the Howard Hughes Medical Institute, the Pew Charitable Belief Latin American Fellows Program, and the MGH Fund for Medical Discovery.